Monteris Medical raises $7m for NeuroBlate

Monteris Medical raised nearly $7 million of a hoped-for $10 million debt-and-options round for the NeuroBlate neurosurgery device it’s developing.

Plymouth, Minn.-based Monteris last month won FDA approval for an investigational device exemption trial of NeuroBlate in patients newly diagnosed with a form of brain cancer called glioblastoma multiforme. The MRI-guided device is designed to ablate, necrotize or coagulate soft tissue during neurosurgery procedures using laser thermotherapy.

A pair of unnamed investors participated in the $6.8 million round, according to a Nov. 18 regulatory filing.

Monteris has said it expects to launch the 12-month IDE study for GBM during the 4th quarter, with enrollment slated for 5 sites in the U.S., evaluating the system in combination with standard-of-care radiation and chemotherapy. In April the company won another IDE from the FDA for a 45-patient study of the device in treating refractory epilepsy.

A year ago a pair of new backers joined a $30 million Series B round for Monteris. NeuroBlate won 510(k) clearance from the FDA and a nod from Health Canada in April 2013.

Building Better Companies at DeviceTalks Minnesota DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as: Navigating the path to market Reimbursement Winning regulatory approval Corporate culture Entering global markets Leadership Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code SAVE15 to save 15%! REGISTER NOW